The Economic Times daily newspaper is available online now.

    BDR Pharma launches generic cancer drug in India

    Synopsis

    BDR Pharmaceuticals on Wednesday said it has launched the generic version of Lenvatinib drug for the treatment of various types of cancers in India.

    rrAgencies
    BDR Pharmaceuticals on Wednesday said it has launched the generic version of Lenvatinib drug for the treatment of various types of cancers in India. The generic version of the drug has been launched under the brand name 'Bdfoie' in the country.

    The capsules are used for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer, BDR Pharma said in a statement. The results of clinical trials showed encouraging results with safety and efficacy on patients with aggressive tumours, it added. The drug is priced at Rs 1,620 (4 mg) and Rs 2,970 (10 mg) for a pack of 10 capsules, the statement said.

    "By launching cost-effective therapy options we want to mitigate the challenges faced by Indian patients in seeking access to treatment and finding a timely cure for life threatening diseases," BDR Pharmaceuticals CMD Dharmesh Shah said.


    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more

    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more
    The Economic Times

    Stories you might be interested in